BRPI0511036A - formulações de solução farmacêuticas contendo 17-aag - Google Patents

formulações de solução farmacêuticas contendo 17-aag

Info

Publication number
BRPI0511036A
BRPI0511036A BRPI0511036-0A BRPI0511036A BRPI0511036A BR PI0511036 A BRPI0511036 A BR PI0511036A BR PI0511036 A BRPI0511036 A BR PI0511036A BR PI0511036 A BRPI0511036 A BR PI0511036A
Authority
BR
Brazil
Prior art keywords
aag
amount
pharmaceutical solution
volume
solution formulations
Prior art date
Application number
BRPI0511036-0A
Other languages
English (en)
Inventor
Ziyang Zhong
Peter J Licari
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of BRPI0511036A publication Critical patent/BRPI0511036A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAçõES DE SOLUçãO FARMACêUTICAS CONTENDO 17-AAG. A presente invenção refere-se a uma formulação de solução farmacêutica contendo 17-AAG em uma quantidade de até 15 mg/ml dissolvidos em um veículo incluindo (i) um primeiro componente que é etanol, em uma quantidade de entre cerca de 40 e cerca de 60% em volume; (ii) um segundo componente que é óleo de castor polietoxilado, em uma quantidade cerca de 15 a cerca de 50% em volume; e (iii) um terceiro composto que é selecionado do grupo consistindo em propileno glicol, PEG 300, PEG 400, glicerol, e combinações destes, em uma quantidade de entre cerca de 0 a cerca de 35% em volume.
BRPI0511036-0A 2004-05-11 2005-05-06 formulações de solução farmacêuticas contendo 17-aag BRPI0511036A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57021504P 2004-05-11 2004-05-11
US11/123,570 US20050256097A1 (en) 2004-05-11 2005-05-05 Pharmaceutical solution formulations containing 17-AAG
PCT/US2005/016010 WO2005110398A2 (en) 2004-05-11 2005-05-06 Pharmaceutical solution formulations containing 17-aag

Publications (1)

Publication Number Publication Date
BRPI0511036A true BRPI0511036A (pt) 2007-11-27

Family

ID=35310196

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511036-0A BRPI0511036A (pt) 2004-05-11 2005-05-06 formulações de solução farmacêuticas contendo 17-aag

Country Status (10)

Country Link
US (1) US20050256097A1 (pt)
EP (1) EP1744743A2 (pt)
JP (1) JP2007537258A (pt)
AU (1) AU2005244115A1 (pt)
BR (1) BRPI0511036A (pt)
CA (1) CA2565583A1 (pt)
IL (1) IL178689A0 (pt)
MX (1) MXPA06012935A (pt)
RU (1) RU2382643C2 (pt)
WO (1) WO2005110398A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
CA2604473A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either
MX2007013499A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma.
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008055386A1 (fr) * 2006-11-10 2008-05-15 Shenzhen Shengeryimei Biotech Co., Ltd. Composition pharmaceutique hydrosoluble pour injection de 17-allyl amino-17-déméthoxy geldanamycine (17-aag)
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
WO2009009067A2 (en) * 2007-07-09 2009-01-15 Kwon Glen S Micelle encapsulation of theropeutic agents
CA2702082A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
RU2678833C2 (ru) * 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
WO2011038278A2 (en) 2009-09-25 2011-03-31 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
RU2529800C2 (ru) * 2010-03-18 2014-09-27 ИННОФАРМА, Инк. Стабильные составы бортезомиба
WO2012151544A1 (en) 2011-05-05 2012-11-08 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
US10898582B2 (en) 2014-12-11 2021-01-26 University Of Utah Research Foundation Bi-functional allosteric protein-drug molecules for targeted therapy
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
JP2018008922A (ja) * 2015-08-04 2018-01-18 わかもと製薬株式会社 ステロイド白内障の予防及び治療
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US553153A (en) * 1896-01-14 Type-writing machine
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5932556A (en) * 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
EP1014953B1 (en) * 1997-03-05 2012-04-25 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
US20030044434A1 (en) * 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
US6121323A (en) * 1997-12-03 2000-09-19 3M Innovative Properties Company Bishydroxyureas
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
CA2356959C (en) * 1998-12-22 2009-03-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-insoluble drug delivery system
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
TW471968B (en) * 1999-08-25 2002-01-11 Committee On Chinese Medicine Solamargine pharmaceutical composition for killing cancer cells
US20020037855A1 (en) * 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
US6946456B2 (en) * 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
ES2298286T3 (es) * 2000-10-31 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Formulaciones de dosis orales auto-emulsionantes de inhibidores de proteasa de piranona.
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
PT1373215E (pt) * 2001-03-30 2006-12-29 Uni S Of A R By The S D Of H H Derivado de geldanamicina e metodo de tratamento de cancro utilizando o mesmo
EP1392283A4 (en) * 2001-05-16 2004-10-20 Cytovia Inc SUBSTITUTED CUMARINE AND CHINOLINE AS CASPASE ACTIVATORS
US6962944B2 (en) * 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
IL162293A0 (en) * 2001-12-19 2005-11-20 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20030232078A1 (en) * 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Also Published As

Publication number Publication date
IL178689A0 (en) 2007-02-11
RU2006143666A (ru) 2008-06-20
RU2382643C2 (ru) 2010-02-27
CA2565583A1 (en) 2005-11-24
WO2005110398A2 (en) 2005-11-24
AU2005244115A1 (en) 2005-11-24
JP2007537258A (ja) 2007-12-20
WO2005110398A3 (en) 2006-05-04
EP1744743A2 (en) 2007-01-24
US20050256097A1 (en) 2005-11-17
MXPA06012935A (es) 2007-01-26

Similar Documents

Publication Publication Date Title
CO6400138A2 (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
WO2005110398A3 (en) Pharmaceutical solution formulations containing 17-aag
JP2020007370A (ja) ルリコナゾール含有外用医薬組成物
WO2006052921A3 (en) Cyclodextrin solubilizers for liquid and semi-solid formulations
EA201170543A1 (ru) Жидкий фармацевтический состав, содержащий парацетамол
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
JP2007537258A5 (pt)
NO20000466D0 (no) Farmasoeytisk preparat for sure, lipofile forbindelser i form av en selvemulgerende formulering
BRPI0409440A (pt) composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
ES2399569T3 (es) Composición farmacéutica líquida estable a base de trazodona
BRPI0409413A (pt) composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável
DE602004018647D1 (de) Galloylpeptide
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
MX2012010935A (es) Formulacion acuosa estable mejorada de (e)-4-carboxiestiril-4-clor obencil sulfona.
NO20070832L (no) Farmasoytiske preparat av piperazinderivater.
JP2006312628A (ja) アシタザノラスト含有水性組成物
DE602005009110D1 (de) Injektierbare wässrige Paclitaxel-Lösungen und Verfahren zu ihrer Herstellung
JP5052028B2 (ja) アシタザノラスト含有組成物

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.